# Alnylam: how the business works

> For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Alnylam Pharmaceuticals, Inc. · NASDAQ: ALNY · Sector: Health Care

Updated for Q3 FY2026 · checked Nov 20, 2026

This is the plain-text version of https://cityfort.co/stocks/alnylam. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Alnylam: how the business works", with the page URL.

## The 30-second summary

Alnylam makes RNAi medicines that silence one harmful gene, and had $3.71 billion of revenue in FY2025, 62.3% of it from AMVUTTRA. Distributors buy its four medicines, while partners such as Roche and Novartis pay milestones and royalties. FY2025 brought $313.7 million of net income, the first full-year profit from FY2021 to FY2025.

## 5 points

- **What it sells:** Alnylam sells RNAi medicines that silence one harmful gene, and AMVUTTRA, for ATTR amyloidosis, was 62.3% of its $3.71 billion FY2025 revenue. [S3]
- **Who pays it:** Sales of Alnylam's four medicines were 80.4% of its FY2025 revenue, research partners such as Roche 14.9% and Novartis's Leqvio royalties 4.7%. [S3]
- **What it keeps from $100:** Of every $100 that came in during FY2025, Alnylam kept $8.2 as net income after $34.5 on research and $31.6 on selling and admin; that $100 includes $116.7 million of interest and other income, and EBITDA from operations was $557 million. [S3]
- **Where the operating profit comes from:** Alnylam reports one business segment and no profit by medicine; it turned profitable as revenue grew 103% from FY2023 to FY2025 while R&D grew 31%. [S3]
- **The one thing to watch:** AMVUTTRA brought in $1.13 billion in Q3 FY2026, and on Jul 30, 2026 Alnylam lowered its FY2026 TTR guidance to $4.2–4.5 billion. [S20, S18]

## What does Alnylam sell?

Alnylam makes RNAi medicines. Each one silences a single gene in the liver, so the body makes less of a harmful protein. It sells four such medicines itself and earns royalties and payments on others that partners sell.

- **AMVUTTRA (vutrisiran):** Treats ATTR amyloidosis, where a liver protein called TTR builds up in nerves and the heart. Approved in the US for the nerve form in June 2022 and the heart form (ATTR-CM) in March 2025. Sales were $2.31 billion in FY2025. [S3]
- **ONPATTRO (patisiran):** An older TTR medicine for the nerve form, the first RNAi medicine approved by the FDA. Sales fell 32% to $172.8 million in FY2025, with fewer patients on it. [S3]
- **GIVLAARI (givosiran):** For acute hepatic porphyria, a rare liver disease. Sales were $308.5 million in FY2025, up 21%. [S3]
- **OXLUMO (lumasiran):** For primary hyperoxaluria type 1, a rare disease. Sales were $191.4 million in FY2025, up 15%. [S3]
- **Leqvio and Qfitlia (sold by partners):** Novartis sells Leqvio (inclisiran) and pays Alnylam royalties: $174.0 million in FY2025. Sanofi sells Qfitlia (fitusiran), approved by the FDA in March 2025 to prevent bleeding episodes. [S3, S1]
- **Partner research deals:** Roche, Regeneron and others pay for rights to Alnylam drug candidates. Collaboration revenue was $553.4 million in FY2025, including a $300.0 million Roche milestone. [S3]

## Who pays Alnylam?

- **Buyers of its medicines (80.4% of revenue):** Customers that buy its four medicines; the largest, an unnamed distributor, was 45% of gross revenue. Net product revenue was $2.99 billion in FY2025. [S3]
- **Research partners (14.9% of revenue):** Roche ($394.9 million in FY2025), Regeneron ($114.0 million) and others pay for rights and milestones. [S3]
- **Novartis (royalties) (4.7% of revenue):** Pays royalties on its global Leqvio sales. Alnylam sold half of these royalties to a Blackstone affiliate in April 2020. [S3, S1]
- **Customer concentration:** largest customer 45.0% of revenue. One distributor, unnamed in the FY2025 10-K and called Distributor A, was 45% of gross revenue in FY2025, up from 29% in FY2024 and 28% in FY2023. It also owed 45% of gross receivables at Dec 31, 2025. [S3]

## Where the money went (FY2025)

1. Alnylam took in $3.71 billion of revenue in FY2025, plus $116.7 million of interest and other income.
2. Making the medicines, including royalties Alnylam pays on AMVUTTRA, cost $681.9 million.
3. Research took $1.32 billion and selling and admin $1.21 billion.
4. Interest on debt took $252.6 million, and buying back convertible notes cost another $42.5 million.
5. After $9.4 million of tax, $313.7 million was left as net income, the only full-year profit from FY2021 to FY2025.

Sources: S3.

## Key numbers by year (US$ million)

Financials: consolidated, US$ million. Fiscal years are the company's own: Fiscal year ends Dec 31 (the calendar year). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (US$ per share, diluted) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY2021 | 844.3 | −661.1 | −78.3% | −852.8 | −101.0% | −7.2 | −641.7 | 76.4 | −718.1 | S13 |
| FY2022 | 1,037.4 | −740.6 | −71.4% | −1,131.2 | −109.0% | −9.3 | −541.3 | 72.1 | −613.3 | S12 |
| FY2023 | 1,828.3 | −228.1 | −12.5% | −440.2 | −24.1% | −3.52 | 104.2 | 62.2 | 41.9 | S11 |
| FY2024 | 2,248.2 | −120.2 | −5.3% | −278.2 | −12.4% | −2.18 | −8.3 | 34.3 | −42.6 | S7 |
| FY2025 | 3,713.9 | 557.2 | 15.0% | 313.7 | 8.4% | 2.33 | 524.1 | 58.7 | 465.4 | S3 |

- EBITDA here = operating income plus depreciation and amortization (from the cash flow statement).
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of Sep 30, 2026, US$ million)

At Sep 30, 2026 Alnylam's cash and marketable securities of $3.59 billion were $2.57 billion more than the $1.01 billion carrying value of its convertible notes (Cityfort calculation from the Q3 FY2026 10-Q). [S1, S3, S20, S25]

| Item | Value |
| --- | --- |
| Total debt | 1,012.6 |
| Cash and investments | 3,587.3 |
| Net debt (debt minus cash) | −2,574.6 |
| Net worth (shareholders' money) | 3,603.9 |
| Debt to equity (times) | 0.28 |

- Debt here is the two convertible notes, bonds that can be swapped for shares. About $362.8 million of 1.00% notes is due Sep 15, 2027, and $661.3 million of 0.00% notes is due Sep 15, 2028.
- Not counted as debt: $1.73 billion of liabilities from selling future royalties and taking development funding, mainly from a Blackstone affiliate, at Sep 30, 2026. The company repays them from Leqvio royalties and milestones.
- Also not counted: operating lease liabilities of $249.4 million at Sep 30, 2026.
- A $500 million revolving credit line, available to Sep 30, 2030 and secured by substantially all assets, had no borrowings at Sep 30, 2026.
- Equity rose from $789.2 million at Dec 31, 2025 to $3.60 billion at Sep 30, 2026. Q3 FY2026 net income included a non-cash tax benefit of about $1.9 billion.
- Debt to equity is the convertible notes ÷ stockholders’ equity of $3.60 billion (Cityfort calculation from the Q3 FY2026 10-Q).

## Who owns Alnylam? (as of Jan 31, 2026)

Alnylam has one class of stock with one vote per share, and no holder controls it. Its 15 directors and executive officers held 1,139,927 shares on Jan 31, 2026, including 1,000,428 they could acquire within 60 days. The proxy shows this as less than 1% (0.9%, Cityfort calculation from the 2026 proxy statement). Holder rows have different dates and are never added. [S28, S1]

- Officers and directors (as a group), shares: 0.9%

| Class | Shares (millions) | Votes per share | % of shares | % of votes | Traded | Sources |
| --- | --- | --- | --- | --- | --- | --- |
| Common stock (133,937,576 shares on Oct 23, 2026 (Q3 FY2026 10-Q cover). Alnylam has one class of common stock.) | 133.94 | 1 | — | — | Yes | S1 |

Holders of 5% or more (each row shows the date of its own filing):

| Holder | Shares | Votes | As of | Note | Sources |
| --- | --- | --- | --- | --- | --- |
| FMR LLC | 12.7% | — | Nov 5, 2025 | 16,834,095 shares, from a Schedule 13G/A filed Nov 5, 2025, as listed in the 2026 proxy statement. | S28 |
| Capital World Investors | 12.4% | — | Feb 9, 2024 | 16,398,889 shares, from a Schedule 13G/A filed Feb 9, 2024. This is old data. | S28 |
| The Vanguard Group | 9.8% | — | Apr 7, 2025 | 13,056,605 shares, from a Schedule 13G/A filed Apr 7, 2025. | S28 |
| BlackRock, Inc. | 6.4% | — | Jan 26, 2024 | 8,546,557 shares, from a Schedule 13G/A filed Jan 26, 2024. This is old data. | S28 |
| Capital Research Global Investors | 5.3% | — | Feb 13, 2025 | 6,968,513 shares, from a Schedule 13G filed Feb 13, 2025. | S28 |

## What could go wrong

### One medicine brings in most of the money

AMVUTTRA was 62.3% of FY2025 revenue and $1.13 billion of $1.46 billion in Q3 FY2026. ONPATTRO sales fell from $39.1 million in Q3 FY2025 to $19.6 million in Q3 FY2026. [S3, S20]

What to watch: AMVUTTRA sales each quarter against the FY2026 TTR guidance of $4.2–4.5 billion.

### Pills with lower list prices

In the heart form, AMVUTTRA competes with Pfizer’s VYNDAQEL/VYNDAMAX and BridgeBio’s ATTRUBY, pills with lower US list prices. Other companies have heart-form drugs in Phase 3 trials. [S1]

What to watch: Trial results from rivals and AMVUTTRA second-line demand.

### One distributor is 45% of revenue

An unnamed distributor was 45% of gross revenue in FY2025 and owed 45% of gross receivables at Dec 31, 2025. [S3]

What to watch: The customer concentration note in the FY2026 10-K.

### Government subpoena on price reporting

In October 2025 the US Attorney's Office for the District of Massachusetts subpoenaed documents on all four of Alnylam's own medicines. It covers government price reporting and fee and discount arrangements with distributors. Alnylam says it is producing records. The FY2025 10-K says no material loss contingencies were accrued at Dec 31, 2025. [S1, S3]

What to watch: Updates in the legal note of each 10-Q and 10-K.

### US drug pricing rules

The Q3 FY2026 10-Q names the Inflation Reduction Act, Medicare reimbursement changes and the 340B drug pricing program as possible pressures on demand and prices. [S1]

What to watch: Medicare price rules and 340B changes named in filings.

### Royalty and funding obligations

Beyond $1.01 billion of convertible notes, Alnylam carried $1.73 billion of liabilities at Sep 30, 2026 from selling future royalties and taking development funding. In Q3 FY2026, interest on them included about $58 million for the Leqvio royalty liability and $23 million for development funding. [S1, S20]

What to watch: Payments to the Blackstone affiliate and the 2027 notes due Sep 15, 2027.

### Patent challenges

The Q3 FY2026 10-Q says generic makers can challenge listed patents, and a successful challenge could bring generic competition sooner. [S1]

What to watch: Any patent challenge notices disclosed for AMVUTTRA.

## What to watch

Next: Q4 FY2026 results, Date not announced yet.

- **AMVUTTRA sales against guidance:** AMVUTTRA brought in $1.13 billion in Q3 FY2026. On Oct 29, 2026 Alnylam reiterated FY2026 TTR guidance of $4.2–4.5 billion.
- **FDA decision on cemdisiran:** The Q3 FY2026 earnings release gives an FDA date in November 2026 for Regeneron's cemdisiran. If approved, Alnylam is eligible for royalties of up to 15% on its sales.
- **Share buyback:** The board authorized a $1.0 billion buyback on Nov 2, 2026. Alnylam said on Nov 5, 2026 it plans to buy about $500 million by the end of 2026.
- **Government subpoena:** A subpoena from the US Attorney's Office in Massachusetts in October 2025 asks for records on price reporting and distributor fees. Updates appear in the legal note of each 10-Q and 10-K.

## Sources

- S1: Form 10-Q for Q3 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/0001178670-26-000076-index.htm (published Oct 29, 2026)
- S2: Form 10-Q for Q2 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/0001178670-26-000062-index.htm (published Jul 30, 2026)
- S3: Form 10-K for FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/0001628280-26-007497-index.htm (published Feb 12, 2026)
- S4: Form 10-Q for Q3 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000162828025047345/0001628280-25-047345-index.htm (published Oct 30, 2025)
- S5: Form 10-Q for Q2 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000117867025000090/0001178670-25-000090-index.htm (published Jul 31, 2025)
- S6: Form 10-Q for Q1 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000117867025000052/0001178670-25-000052-index.htm (published May 1, 2025)
- S7: Form 10-K for FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/0001178670-25-000026-index.htm (published Feb 13, 2025)
- S8: Form 10-Q for Q3 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000117867024000053/0001178670-24-000053-index.htm (published Oct 31, 2024)
- S9: Form 10-Q for Q2 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/0001178670-24-000041-index.htm (published Aug 1, 2024)
- S10: Form 10-Q for Q1 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/0001178670-24-000023-index.htm (published May 2, 2024)
- S11: Form 10-K for FY2023. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000117867024000008/0001178670-24-000008-index.htm (published Feb 15, 2024)
- S12: Form 10-K for FY2022. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000117867023000005/0001178670-23-000005-index.htm (published Feb 23, 2023)
- S13: Form 10-K for FY2021. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000117867022000013/0001178670-22-000013-index.htm (published Feb 10, 2022)
- S14: Form 10-Q for Q1 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000162828026028605/alny-20260331.htm (published Apr 30, 2026)
- S15: Earnings release for Q1 FY2026 (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000162828026028601/alny2026q1earningsrelease.htm (published Apr 30, 2026)
- S16: 8-K May 27, 2026: annual meeting results, board appointment (Items 5.02/5.07). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/alny-20260520.htm (published May 27, 2026)
- S17: 8-K Sep 10, 2025: convertible notes offering announcement (Item 8.01). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000119312525199686/d72540d8k.htm (published Sep 10, 2025)
- S18: Earnings release for Q2 FY2026 (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000117867026000060/alny2026q2earningsrelease.htm (published Jul 30, 2026)
- S19: 8-K Sep 12, 2025: 0.00% Convertible Senior Notes due 2028 closing, $575.0M (Items 1.01/2.03/3.02). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000119312525202366/d949176d8k.htm (published Sep 12, 2025)
- S20: Earnings release for Q3 FY2026 (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000117867026000074/alny2026q3earningsrelease.htm (published Oct 29, 2026)
- S21: 8-K Nov 5, 2026: Chief Commercialization Officer departure and $1.0 billion share repurchase program (Items 5.02/8.01). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000117867026000080/alny-20261102.htm (published Nov 5, 2026)
- S22: 8-K Oct 3, 2025: Credit Agreement, $500M revolver (Item 1.01). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000119312525230201/d19737d8k.htm (published Oct 3, 2025)
- S23: Earnings release for Q3 FY2025 (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000162828025047342/alny2025q3earningsrelease.htm (published Oct 30, 2025)
- S24: 8-K Dec 3, 2025: two directors resign (Item 5.02). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000162828025055084/alny-20251202.htm (published Dec 3, 2025)
- S25: 8-K Dec 11, 2025: repurchase of 1.00% notes due 2027 (Item 8.01). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000119312525315047/d201569d8k.htm (published Dec 11, 2025)
- S26: Earnings release for Q4 and full year FY2025 (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000162828026007491/alny2025q4earningsrelease.htm (published Feb 12, 2026)
- S27: 8-K Mar 4, 2026: special performance-based equity award to CEO (Item 5.02). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000162828026014728/alny-20260302.htm (published Mar 4, 2026)
- S28: Proxy statement (DEF 14A) for the 2026 annual meeting. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1178670/000162828026023923/alny-20260406.htm (published Apr 6, 2026)
